var _paq = window._paq = window._paq || []; /* tracker methods like "setCustomDimension" should be called before "trackPageView" */ _paq.push(['trackPageView']); _paq.push(['enableLinkTracking']); (function() { var u="https://rwrregs.matomo.cloud/"; _paq.push(['setTrackerUrl', u+'matomo.php']); _paq.push(['setSiteId', '1']); var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.data-privacy-src='//cdn.matomo.cloud/rwrregs.matomo.cloud/matomo.js'; s.parentNode.insertBefore(g,s); })();

Real World Evidence (RWE) 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?

RWE 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?

Retrospective data generally refers to data that has already been collected for another purpose and is being used retrospectively to answer a new research question. This data can come from various sources, such as electronic health records, claims databases, or patient registries, and is often used to generate RWE.

On the other hand, secondary use of existing data refers to the practice of using existing data for a purpose other than the one for which it was originally collected. This can include using data from clinical trials for post-market surveillance or using data from a patient registry for comparative effectiveness research.

While retrospective data can be one type of existing data that is used for secondary purposes, not all secondary uses of data involve retrospective data. For example, prospective data collected for one purpose, such as routine clinical care, can be used for secondary purposes, such as generating RWE.

In summary, retrospective data and secondary use of existing data are related but not interchangeable terms in the context of RWE. Retrospective data is a type of existing data that can be used for secondary purposes, but not all secondary uses of data involve retrospective data.

Share this story...

Real World Evidence (RWE) 101 – Is ‘Retrospective Data’ the Same as ‘Secondary Use of Existing Data’?2023-08-07T23:11:48+00:00

Real World Evidence (RWE) 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?

RWE 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?

The GDPR (General Data Protection Regulation) includes provisions that support the secondary use of existing health data for scientific research purposes, while also protecting the privacy and data protection rights of individuals.

One of the key ways that the GDPR supports the secondary use of health data for research is through the concept of “legitimate interests”. Article 6(1)(f) of the GDPR allows for the processing of personal data if it is necessary for the legitimate interests of the data controller or a third party, provided that those interests do not override the fundamental rights and freedoms of the data subject. Scientific research can be considered a legitimate interest, provided that appropriate safeguards are in place to protect individuals’ rights and freedoms.

In addition, the GDPR includes provisions that specifically address the use of health data for scientific research. For example, Article 9(2)(j) allows for the processing of special categories of personal data, such as health data, for scientific research purposes, provided that appropriate safeguards are in place.

The GDPR also requires that data controllers implement appropriate technical and organizational measures to ensure the security and confidentiality of personal data, including health data. This includes requirements for data pseudonymization and encryption, as well as procedures for data breach notification.

Overall, the GDPR strikes a balance between protecting individuals’ privacy and data protection rights, and supporting the important public interest in scientific research. By providing a framework for the responsible and transparent use of health data for research purposes, the GDPR can help to facilitate the development of new treatments and interventions that can improve public health outcomes.

Share this story...

Real World Evidence (RWE) 101 – EHDS and GDPR – How does GDPR support the secondary use of existing health data for the purposes of scientific research?2023-08-07T23:09:58+00:00

Real World Evidence (RWE) 101 – Federated Clinical Data

RWE 101 – Federated Clinical Data

Federated clinical data refers to clinical data that is distributed across multiple organizations or entities, such as hospitals, clinics, research institutions, or public health agencies. This data may include patient demographic information, medical history, clinical diagnoses, laboratory results, and treatment outcomes, among other types of data.

Federated clinical data allows for the integration of data from multiple sources, which can provide a more comprehensive view of patient health and disease patterns. It also enables healthcare organizations and researchers to collaborate and share data in a secure and efficient manner.

In a federated clinical data model, each organization retains control over its own data, while sharing selected data with other entities for specific purposes, such as research studies or public health surveillance. This approach helps to ensure patient privacy and data security, while still allowing for the sharing of valuable information to advance healthcare and medical research.

The use of federated clinical data is becoming increasingly common as healthcare organizations seek to harness the power of big data and machine learning to improve patient outcomes, develop new treatments, and reduce healthcare costs.

Share this story...

Real World Evidence (RWE) 101 – Federated Clinical Data2023-08-07T23:08:55+00:00

Real World Evidence (RWE) 101 – The European Health Data Space (EHDS)

RWE 101 – The European Health Data Space (EHDS)

The European Health Data Space (EHDS) is a proposed initiative by the European Union to create a secure and cross-border platform for the sharing and use of health data in the European Union. The EHDS aims to improve the quality and accessibility of health data, promote innovation in healthcare, and support research and innovation in the field of health.

The EHDS will build on existing initiatives and policies related to health data in the EU, including the General Data Protection Regulation (GDPR), the Electronic Health Record Exchange Format (EHRxf), and the European Health Insurance Card (EHIC). The initiative will also leverage emerging technologies, such as artificial intelligence and blockchain, to enhance the security, interoperability, and utility of health data.

The EHDS will focus on several key areas of health data, including electronic health records (EHRs), patient registries, medical imaging data, genomic data, and health administrative data. The initiative will establish a legal and technical framework for the sharing and use of this data, while ensuring that data privacy and security are maintained.

One of the key objectives of the EHDS is to promote the use of health data for research and innovation in healthcare. The initiative will facilitate the sharing of health data across borders and promote collaboration among researchers, clinicians, and industry partners. This is expected to lead to the development of new treatments, therapies, and medical devices, as well as improvements in healthcare delivery and outcomes.

The EHDS will also aim to improve the quality and accessibility of healthcare services by providing clinicians and patients with access to comprehensive and up-to-date health information. This will support more effective and personalized treatment decisions, as well as more efficient and coordinated healthcare delivery.

Overall, the European Health Data Space is an ambitious initiative that seeks to leverage the potential of health data to improve healthcare and drive innovation in the field. While the initiative is still in its early stages, it has the potential to transform healthcare in the European Union and to establish the EU as a leader in the use of health data for the public good.

Share this story...

Real World Evidence (RWE) 101 – The European Health Data Space (EHDS)2023-08-07T23:07:39+00:00

Real World Evidence (RWE) 101 – The Impact of the EMAs Data Quality Framework on RWE

RWE 101 – The Impact of the EMAs Data Quality Framework on RWE

The EMA (European Medicines Agency) data quality framework provides a set of guidelines and principles for ensuring high-quality data in real-world evidence (RWE) studies in the context of EU medicines regulation. The framework aims to promote the use of RWE in the assessment of medicines, and to ensure that RWE studies are conducted in a rigorous and reliable manner.

The impact of the EMA data quality framework on RWE can be significant. By promoting high-quality data collection and analysis in RWE studies, the framework can help to ensure that the results of such studies are reliable and can be used to inform regulatory decision-making. This, in turn, can facilitate the timely access of patients to new treatments and can help to improve public health outcomes.

The framework encourages the use of transparent and reproducible methods in RWE studies, which can help to ensure that the results are credible and trustworthy. The use of standardized data collection and analysis methods can also facilitate the comparison of results across different studies and settings, which can help to build a more comprehensive understanding of the safety and efficacy of medicines.

Overall, the EMA data quality framework can help to promote the use of RWE in medicines regulation and improve the quality and reliability of RWE studies. This can have a positive impact on public health by facilitating timely access to new treatments and improving the understanding of the safety and efficacy of medicines.

Share this story...

Real World Evidence (RWE) 101 – The Impact of the EMAs Data Quality Framework on RWE2023-08-07T23:06:32+00:00

Real World Evidence (RWE) 101 – DARWIN-EU

RWE 101 – DARWIN-EU

DARWIN-EU is a project that aims to establish a sustainable platform for generating and using real-world evidence (RWE) to support decision-making in healthcare across Europe. The project brings together a consortium of academic institutions, patient organizations, regulatory authorities, and industry partners to build a comprehensive RWE ecosystem that supports the development, regulation, and reimbursement of innovative healthcare products and services.

The DARWIN-EU project focuses on several key areas of RWE, including data collection, data quality and management, data analytics and interpretation, and data sharing and dissemination. The project aims to address the current gaps in RWE infrastructure in Europe and to facilitate the integration of RWE into decision-making processes across the healthcare sector.

One of the key objectives of DARWIN-EU is to establish a European Health Data Space (EHDS) that enables secure and standardized sharing of health data across Europe. The EHDS will support the collection of RWE from a variety of sources, including electronic health records, claims data, patient registries, and clinical trials. The data collected through the EHDS will be analyzed using advanced analytics tools to generate insights into healthcare outcomes, patient populations, and treatment effectiveness.

Another objective of DARWIN-EU is to develop new methods and tools for analyzing and interpreting RWE. This includes the development of machine learning algorithms, natural language processing tools, and other advanced analytics techniques to help identify patterns and insights in large datasets. The project also aims to develop new methods for integrating RWE with other sources of healthcare data, such as genomic data and patient-reported outcomes.

Overall, DARWIN-EU is an important initiative in the context of RWE because it seeks to establish a sustainable infrastructure for collecting, analyzing, and using RWE to support decision-making in healthcare. The project has the potential to generate valuable insights into healthcare outcomes, patient populations, and treatment effectiveness, and to inform the development and regulation of innovative healthcare products and services.

Share this story...

Real World Evidence (RWE) 101 – DARWIN-EU2023-08-07T23:05:29+00:00

Real World Evidence (RWE) 101 – Registry vs Registry-Based Study

RWE 101 – Registry vs Registry-Based Study

In the context of real-world evidence, a registry is a collection of data on a particular disease, medical condition, or treatment that is recorded over time. A registry-based study, on the other hand, is a research study that uses data from a registry to evaluate the safety or effectiveness of a particular treatment or medical intervention.

A registry is typically created to collect data on a particular population, such as patients with a specific medical condition or those who have been treated with a particular medication. The data collected in a registry may be observational or experimental, and can include demographic information, medical history, treatment information, and outcomes.

A registry-based study, on the other hand, is a research study that uses data from a registry to evaluate the safety or effectiveness of a particular treatment or medical intervention. In a registry-based study, researchers analyze the data collected in a registry to answer specific research questions, such as whether a particular treatment is effective in improving patient outcomes, or whether there are any safety concerns associated with a specific medication.

The main difference between a registry and a registry-based study is that a registry is a database of information, while a registry-based study is a research study that uses data from a registry. Registries can be used for a variety of purposes, including monitoring the safety and effectiveness of treatments, tracking disease incidence and prevalence, and identifying gaps in care. Registry-based studies are one way to use the data collected in a registry to generate new knowledge and insights about a particular disease or treatment.

Overall, both registries and registry-based studies are important tools for collecting and analyzing real-world evidence, and can provide valuable information to healthcare providers, patients, and researchers about the safety and effectiveness of medical interventions.

Share this story...

Real World Evidence (RWE) 101 – Registry vs Registry-Based Study2023-08-07T23:04:25+00:00

Real World Evidence (RWE) 101 – Pregnancy Registries

RWE 101 – Pregnancy Registries

A pregnancy registry is a type of real-world evidence collection system that collects data from pregnant women who have been exposed to a particular medication, vaccine, or medical intervention during pregnancy. The purpose of a pregnancy registry is to gather information about the safety and effectiveness of these exposures in pregnant women and their offspring.

Pregnancy registries are important because pregnant women are often excluded from clinical trials due to safety concerns, which can limit the amount of data available about the safety and effectiveness of medications, vaccines, and medical inyterventions during pregnancy. By collecting data from pregnant women who have been exposed to these agents, pregnancy registries can provide valuable information to healthcare providers and patients to help guide treatment decisions during pregnancy.

A pregnancy registry typically collects information about the mother’s health status, the medication or medical intervention being studied, and pregnancy outcomes such as miscarriage, stillbirth, preterm birth, and birth defects. The data collected can be used to identify potential safety signals or adverse effects associated with the medication or medical intervention, and to evaluate the overall safety and effectiveness of the treatment in pregnant women.

In summary, pregnancy registries are an important tool in real-world evidence collection for understanding the safety and effectiveness of medications, vaccines, and medical interventions during pregnancy. By gathering data from pregnant women who have been exposed to these agents, pregnancy registries can provide valuable information to healthcare providers and patients to help guide treatment decisions and improve the health outcomes of both mother and child.

Share this story...

Real World Evidence (RWE) 101 – Pregnancy Registries2023-08-07T23:03:15+00:00

Real World Evidence (RWE) 101 – Diversity

RWE 101 – Diversity

Diversity in the context of real-world research refers to the inclusion of individuals from different backgrounds, including but not limited to race, ethnicity, gender, age, sexual orientation, socioeconomic status, and geographic location. It is important to ensure diversity in research because it can provide a more comprehensive understanding of health and healthcare outcomes, as well as enable the development of interventions that are effective for all populations.

In the past, research has often focused on populations that are easier to access, which has led to underrepresentation of certain groups in research studies. This lack of diversity can result in biased and incomplete research findings that do not accurately reflect the experiences and health outcomes of all populations.

Therefore, it is crucial for real-world research to include diverse populations to ensure that research findings can be generalized to all groups. This can help to identify health disparities, understand the root causes of these disparities, and develop interventions that are effective for all populations.

In summary, diversity in real-world research means including individuals from diverse backgrounds to ensure that research findings are inclusive, representative, and generalizable to all populations. By doing so, research can more effectively identify and address health disparities and improve health outcomes for all individuals.

Share this story...

Real World Evidence (RWE) 101 – Diversity2023-08-07T23:02:07+00:00

Real World Evidence (RWE) 101 – The Patient Voice

RWE 101 – The Patient Voice

The patient voice refers to the perspectives, opinions, and experiences of patients and their families or caregivers in the context of healthcare research. It is a term used to describe the active involvement of patients in the design, execution, and dissemination of research studies that aim to improve health outcomes and patient care.

In the past, patients were often viewed as passive recipients of healthcare services and were not considered to have an active role in research. However, in recent years, there has been a growing recognition of the importance of including the patient voice in healthcare research. This recognition is driven by the belief that patients have unique insights and perspectives that can help researchers better understand their experiences, preferences, and priorities.

The patient voice is particularly important in real-world research, which focuses on understanding healthcare outcomes in the context of everyday clinical practice. By including patients in the research process, researchers can ensure that the research questions and outcomes are relevant and meaningful to patients. This can lead to more patient-centered research that has the potential to improve patient outcomes and quality of life.

Overall, the patient voice is an essential component of real-world research, as it helps to ensure that research is conducted in a way that is responsive to the needs and priorities of patients.

Share this story...

Real World Evidence (RWE) 101 – The Patient Voice2023-08-07T23:00:50+00:00
Help

About Us

Contact Us

Our Values

SSO Login

Follow Us

Newsletter

LinkedIn

[…]

Legal Info

Privacy Policy

Terms and Conditions

Copyright 2026 | Real-World Research Limited | All Rights Reserved |

This website uses cookies and third party services. Settings OK Reject

Cookies

We use analytical tools (Google Analytics) to help us improve the user experience. We DO NOT sell or use any of this data for any purpose beyond improving the design and usability of our own website (rwr-regs.com).
Go to Top